{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:21:51Z","timestamp":1790097711120,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03356-8","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T06:44:34Z","timestamp":1757659474000},"page":"5627-5638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessing the Benefits of Rapid Start Antiretroviral Therapy for Newly Diagnosed People with HIV in the United States"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7728-0587","authenticated-orcid":false,"given":"Patrick S.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3923-5794","authenticated-orcid":false,"given":"Cillian","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-8581","authenticated-orcid":false,"given":"James","family":"Jarrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3663-9055","authenticated-orcid":false,"given":"Uche","family":"Mordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8248-7697","authenticated-orcid":false,"given":"Nikos","family":"Kotsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4200-3106","authenticated-orcid":false,"given":"Rui","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2369-360X","authenticated-orcid":false,"given":"Hansel E.","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"7","key":"3356_CR1","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/ciu1137","volume":"60","author":"MJ Siedner","year":"2015","unstructured":"Siedner MJ, Ng CK, Bassett IV, et al. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002\u20132013: a meta-analysis. Clin Infect Dis. 2015;60(7):1120\u20137.","journal-title":"Clin Infect Dis"},{"issue":"16","key":"3356_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","volume":"324","author":"MS Saag","year":"2020","unstructured":"Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2020;324(16):1651\u201369.","journal-title":"JAMA"},{"key":"3356_CR3","unstructured":"Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV 2024 [Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new."},{"issue":"1","key":"3356_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","volume":"32","author":"N Ford","year":"2018","unstructured":"Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32(1):17\u201323.","journal-title":"AIDS"},{"issue":"1","key":"3356_CR5","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1093\/cid\/ciaa620","volume":"73","author":"O Bacon","year":"2021","unstructured":"Bacon O, Chin J, Cohen SE, et al. Decreased time from human immunodeficiency virus diagnosis to care, antiretroviral therapy initiation, and virologic suppression during the citywide RAPID initiative in San Francisco. Clin Infect Dis. 2021;73(1):e122\u20138.","journal-title":"Clin Infect Dis"},{"key":"3356_CR6","unstructured":"Ending the HIV Epidemic (EHE). EHE Overview [Available from: https:\/\/www.hiv.gov\/federal-response\/ending-the-hiv-epidemic\/overview#:~:text=The%20Ending%20the%20HIV%20Epidemic%20in%20the%20U.S.,four%20science-based%20strategies%3A%20diagnose%2C%20treat%2C%20prevent%2C%20and%20respond."},{"issue":"1","key":"3356_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1060028019867970","volume":"54","author":"NV Hastain","year":"2020","unstructured":"Hastain NV, Santana A, Schafer JJ. The incidence and severity of drug interactions before and after antiretroviral therapy simplification in treatment-experienced patients with HIV infection. Ann Pharmacother. 2020;54(1):36\u201342.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"3356_CR8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/09540121.2018.1442554","volume":"30","author":"V Hemmige","year":"2018","unstructured":"Hemmige V, Flash CA, Carter J, Giordano TP, Zerai T. Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment na\u00efve patients. AIDS Care. 2018;30(8):1017\u201324.","journal-title":"AIDS Care"},{"issue":"1","key":"3356_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12160-016-9827-3","volume":"51","author":"Y Chen","year":"2017","unstructured":"Chen Y, Chen K, Kalichman SC. Barriers to HIV medication adherence as a function of regimen simplification. Ann Behav Med. 2017;51(1):67\u201378.","journal-title":"Ann Behav Med"},{"issue":"7","key":"3356_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2025","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2025;333(7):609\u201328.","journal-title":"JAMA"},{"issue":"5","key":"3356_CR11","doi-asserted-by":"publisher","first-page":"135965352312011","DOI":"10.1177\/13596535231201162","volume":"28","author":"A Carr","year":"2023","unstructured":"Carr A, Mackie NE, Paredes R, Ruxrungtham K. HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective. Antivir Ther. 2023;28(5):13596535231201162.","journal-title":"Antivir Ther"},{"issue":"6","key":"3356_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505.","journal-title":"N Engl J Med"},{"key":"3356_CR13","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017."},{"key":"3356_CR14","unstructured":"Duong KN, Schmutz HW, Ben-Umeh KC, et al. Real-world clinical and economic outcomes from rapid start antiretroviral therapy in HIV: systematic review and meta-analysis. AIDS. 2022:10.1097."},{"issue":"8","key":"3356_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","volume":"138","author":"FJ Palella Jr","year":"2003","unstructured":"Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138(8):620\u20136.","journal-title":"Ann Intern Med"},{"issue":"12","key":"3356_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1089\/apc.2014.0194","volume":"28","author":"DA Adedinsewo","year":"2014","unstructured":"Adedinsewo DA, Wei SC, Robertson M, et al. Timing of antiretroviral therapy initiation in a nationally representative sample of HIV-infected adults receiving medical care in the United States. AIDS Patient Care STDs. 2014;28(12):613\u201321.","journal-title":"AIDS Patient Care STDs"},{"issue":"1","key":"3356_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/QAI.0000000000002398","volume":"85","author":"N Crepaz","year":"2020","unstructured":"Crepaz N, Song R, Lyss S, Hall HI. Trends in time from HIV diagnosis to first viral suppression following revised US HIV treatment guidelines, 2012\u20132017. JAIDS J Acquir Immune Defic Syndr. 2020;85(1):46\u201350.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"3356_CR18","first-page":"1832152","volume":"2019","author":"PM Ingabire","year":"2019","unstructured":"Ingabire PM, Semitala F, Kamya MR, Nakanjako D. Delayed Antiretroviral therapy (ART) initiation among Hospitalized adults in a resource-limited settings: a challenge to the global target of ART for 90% of HIV-infected individuals. AIDS Res Treat. 2019;2019(1):1832152.","journal-title":"AIDS Res Treat"},{"issue":"9","key":"3356_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"The INSIGHT START Study Group","year":"2015","unstructured":"The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795\u2013807.","journal-title":"N Engl J Med"},{"issue":"2","key":"3356_CR20","first-page":"129","volume":"26","author":"C Benson","year":"2020","unstructured":"Benson C, Emond B, Lefebvre P, et al. Rapid initiation of antiretroviral therapy following diagnosis of human immunodeficiency virus among patients with commercial insurance coverage. J Manag Care Spec Pharm. 2020;26(2):129\u201341.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"3356_CR21","first-page":"117","volume":"26","author":"C Benson","year":"2020","unstructured":"Benson C, Emond B, Romdhani H, et al. Long-term benefits of rapid antiretroviral therapy initiation in reducing medical and overall health care costs among Medicaid-covered patients with human immunodeficiency virus. J Manag Care Spec Pharm. 2020;26(2):117\u201328.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"3356_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/09540121.2015.1096891","volume":"28","author":"M Robertson","year":"2016","unstructured":"Robertson M, Wei SC, Beer L, et al. Delayed entry into HIV medical care in a nationally representative sample of HIV-infected adults receiving medical care in the USA. AIDS Care. 2016;28(3):325\u201333.","journal-title":"AIDS Care"},{"issue":"4","key":"3356_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096148","volume":"9","author":"S Zhang","year":"2014","unstructured":"Zhang S, McGoy SL, Dawes D, et al. The potential for elimination of racial-ethnic disparities in HIV treatment initiation in the Medicaid population among 14 southern states. PLoS One. 2014;9(4):e96148.","journal-title":"PLoS One"},{"issue":"1","key":"3356_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2022.23617","volume":"329","author":"LC Zalla","year":"2023","unstructured":"Zalla LC, Cole SR, Eron JJ, et al. Association of race and ethnicity with initial prescription of antiretroviral therapy among people with HIV in the US. JAMA. 2023;329(1):52\u201362.","journal-title":"JAMA"},{"key":"3356_CR25","doi-asserted-by":"publisher","first-page":"232595821877404","DOI":"10.1177\/2325958218774042","volume":"17","author":"O Mgbere","year":"2018","unstructured":"Mgbere O, Rodriguez-Barradas M, Vigil KJ, et al. Systemic delays in the initiation of antiretroviral therapy for clinically eligible HIV-infected patients in Houston, Texas: the providers\u2019 report card. J Int Assoc Provid AIDS Care. 2018;17:2325958218774042.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"3356_CR26","doi-asserted-by":"publisher","first-page":"232595822412281","DOI":"10.1177\/23259582241228164","volume":"23","author":"JY Chow","year":"2024","unstructured":"Chow JY, Gao A, Ahn C, Nijhawan AE. Rapid start of antiretroviral therapy in a large urban clinic in the US South: impact on HIV care continuum outcomes and medication adherence. J Int Assoc Prov AIDS Care (JIAPAC). 2024;23:23259582241228164.","journal-title":"J Int Assoc Prov AIDS Care (JIAPAC)"},{"key":"3356_CR27","doi-asserted-by":"crossref","unstructured":"Dalal A, Clark E, Samiezade-Yazd Z, et al., editors. Outcomes and Predictors of Rapid Antiretroviral Therapy Initiation for People With Newly Diagnosed HIV in an Integrated Health Care System. Open Forum Infectious Diseases; 2023: Oxford University Press US.","DOI":"10.2139\/ssrn.4488068"},{"key":"3356_CR28","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet 2025 [Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"3356_CR29","unstructured":"Rona M. Vail M, AAHIVS; Sanjiv S. Shah, MD, MPH, AAHIVS; Steven M. Fine, MD, PhD; Joseph P. McGowan, MD, FACP, FIDSA; Samuel T. Merrick, MD, FIDSA; Anne K. Monroe, MD, MSPH; Jessica Rodrigues, MPH, MS; Christopher J. Hoffmann, MD, MPH; Brianna L. Norton, DO, MPH; Charles J. Gonzalez, MD. NYSDOH AIDS Institute guideline: Rapid ART Initiation: New York State Department of Health AIDS Institute; 2025 [Available from: https:\/\/www.hivguidelines.org\/guideline\/hiv-art-rapid\/."},{"key":"3356_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.puhe.2024.12.008","volume":"239","author":"EG Gram","year":"2025","unstructured":"Gram EG, Biering IE, Olsen O, Gram GJ. Evidence of zero-risk transmission of HIV in the era of antiretroviral therapy: a systematic review and meta-analyses. Public Health. 2025;239:149\u201355.","journal-title":"Public Health"},{"key":"3356_CR31","unstructured":"National Institute of Health and Care Excellance. Cabotegravir with rilpivirine for treating HIV-1 (TA757) - Committee Papers. 2022."},{"issue":"7","key":"3356_CR32","first-page":"891","volume":"27","author":"K Butler","year":"2021","unstructured":"Butler K, Anderson S-J, Hayward O, et al. Cost-effectiveness and budget impact of dolutegravir\/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. J Manag Care Spec Pharm. 2021;27(7):891\u2013903.","journal-title":"J Manag Care Spec Pharm"},{"key":"3356_CR33","doi-asserted-by":"crossref","unstructured":"Colombo GL, Colangeli V, Di Biagio A, et al. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconom Outcomes Res. 2011:197\u2013205.","DOI":"10.2147\/CEOR.S24130"},{"key":"3356_CR34","unstructured":"Kaiser Family Foundation. Medicaid and People with HIV 2023 [Available from: https:\/\/www.kff.org\/hivaids\/issue-brief\/medicaid-and-people-with-hiv\/."},{"issue":"10107","key":"3356_CR35","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063\u201372.","journal-title":"Lancet"},{"issue":"10107","key":"3356_CR36","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382.","journal-title":"Lancet"},{"issue":"8","key":"3356_CR37","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/QAD.0000000000001437","volume":"31","author":"TD Mangal","year":"2017","unstructured":"Mangal TD. Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. AIDS. 2017;31(8):1073\u201382.","journal-title":"AIDS"},{"issue":"11","key":"3356_CR38","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1093\/jac\/dkx276","volume":"72","author":"V Supervie","year":"2017","unstructured":"Supervie V, Assoumou L, Breban R, et al. Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. J Antimicrob Chemother. 2017;72(11):3172\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3356_CR39","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s41669-022-00322-w","volume":"6","author":"V Estrada","year":"2022","unstructured":"Estrada V, G\u00f3rgolas M, Pe\u00f1a JA, et al. Epidemiologic and economic analysis of rapid antiretroviral therapy initiation with bictegravir\/emtricitabine\/tenofovir alafenamide in Spain. PharmacoEconomics-open. 2022;6(3):415\u201324.","journal-title":"PharmacoEconomics-open"},{"issue":"4","key":"3356_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/OLQ.0000000000001366","volume":"48","author":"A Bingham","year":"2021","unstructured":"Bingham A, Shrestha RK, Khurana N, Jacobson EU, Farnham PG. Estimated lifetime HIV\u2013related medical costs in the United States. Sex Transm Dis. 2021;48(4):299\u2013304.","journal-title":"Sex Transm Dis"},{"key":"3356_CR41","doi-asserted-by":"crossref","unstructured":"Cohen JP, Anupindi VR, Doshi R, et al. Estimation of lifetime costs among insured persons with HIV in the United States. PharmacoEconomics-open. 2025.","DOI":"10.1007\/s41669-025-00584-0"},{"key":"3356_CR42","unstructured":"U.S. Bureau of Labor Statistics. BLS data viewer: Consumer Price Index for Medical Care 2025 [Available from: https:\/\/data.bls.gov\/dataViewer\/view\/timeseries\/CUUR0000SAM."},{"key":"3356_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00019053-199711020-00005","volume":"11","author":"JE Siegel","year":"1997","unstructured":"Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies: recommendations from the panel on cost effectiveness in health and medicine. Pharmacoeconomics. 1997;11:159\u201368.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"3356_CR44","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"3356_CR45","unstructured":"Centers for disease control and prevention. HV surveillance supplemental report: Estimated HIV Incidence and Prevalence in the United States, 2018\u20132022 2024 [Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/156513."},{"issue":"5","key":"3356_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25286","volume":"22","author":"SP Masiano","year":"2019","unstructured":"Masiano SP, Martin EG, Bono RS, et al. Suboptimal geographic accessibility to comprehensive HIV care in the US: regional and urban\u2013rural differences. J Int AIDS Soc. 2019;22(5):e25286.","journal-title":"J Int AIDS Soc"},{"key":"3356_CR47","doi-asserted-by":"crossref","unstructured":"INSIGHT Strategic timing of AntiRetroviral treatment study group. Long-term benefits from early antiretroviral therapy initiation in HIV infection. NEJM Evid 2023;2(3):EVIDoa2200302.","DOI":"10.1056\/EVIDoa2200302"},{"key":"3356_CR48","unstructured":"Radix AE, Fine SM, Vail RM, et al. Rapid ART Initiation. 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03356-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03356-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03356-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:03:59Z","timestamp":1762261439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03356-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3356"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03356-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Gilead. Authors Cillian Copeland, Rui Martins and Nikos Kotsopoulos are employees of Global Market Access Solutions, who were paid consultants to Gilead. Authors James Jarrett and Uche Mordi are employees of Gilead. Author Patrick S. Sullivan has received research grants and speaker fees from Gilead Sciences; he has also received research grants from Merck and ViiV Healthcare. Author Hansel E. Tookes has received grants from Gilead Sciences and ViiV Healthcare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}